Drug-Induced Hepatotoxicity Ends Development of Novel HBV Therapy
The phase 2 trial was evaluating the effects of ABI-H2158 in 88 treatment-naïve patients with HBeAg positive or HBeAg negative chronic hepatitis B infection without cirrhosis.
Hepatitis
New Vial Sizes for Bivigam, Nabi-HB Now Available
The new vial sizes are currently in stock and commercially available in the US.
Epclusa Approved for Younger Patients With Chronic Hepatitis C
The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.
New Formulation of Hepatitis B Immune Globulin Launches
HyperHEP B is the Grifol’s new formulation of its hepatitis B immune globulin.
FDA Says Do Not Drink ‘Real Water’ Brand Alkaline Water
As of April 26, there had been 11 probable cases and one suspected case of acute nonviral hepatitis in Nevada
FDA: ‘Real Water’ Alkaline Water May Be Linked to Hepatitis Outbreak
FDA is in beginning stages of investigation; there may be more products connected to hepatitis outbreak
Updates to the 2021 Adult Immunization Schedule
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
FDA to Review 3-Antigen Prophylactic Hepatitis B Vaccine
The vaccine candidate consists of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus.
Use of Direct Acting Antivirals With Potent Inducers Examined in Case Series
While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.
CDC Guidance Issued for Testing, Management of HCP Exposed to Hep C
Baseline testing for HCP should be conducted as soon as possible after exposure, ideally within 48 hours
